title: Radiofrequency treatment for obstructive tonsillar hypertrophy.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of in-office, temperature-controlled radiofrequency submucosal tissue volume reduction using the Somnoplasty procedure for the treatment of symptomatic chronic obstructive tonsillar hypertrophy.
  
  
  METHODS
  A prospective, nonrandomized, 3-phase protocol using in vitro and in vivo studies associated with operative tonsillectomy and clinical procedures performed in-office.
  
  
  METHODS
  Hospital operating room and private practice otolaryngology office.
  
  
  METHODS
  In vitro studies of 14 tonsil specimens following tonsillectomy; in vivo studies of 11 tonsils before tonsillectomy; and clinical procedures performed on 9 adults, ages 24 to 47 years, with symptomatic chronic tonsillar hypertrophy.
  
  
  METHODS
  For phase 1, histologic tissue sections; for phase 2, histologic tissue sections and clinician and patient questionnaires regarding procedure morbidity; and for phase 3, measurements of oropharyngeal airway size and clinician and patient questionnaires regarding procedure morbidity and symptom improvement.
  
  
  RESULTS
  A 2-needle radiofrequency probe ablated tonsil stromal tissue while leaving overlying mucosa and underlying structures intact. On average, oropharyngeal airway was enlarged 12 mm, with a 70.8% calculated reduction in tonsil size. Procedures were well tolerated and had only minimal pain and dysphagia. There were no episodes of hemorrhage, and patients resumed normal activity within 1 to 2 days. Substantial improvement was reported in daytime sleepiness, snoring, voice clarity, swallowing, and throat irritation.
  
  
  CONCLUSIONS
  Temperature-controlled radiofrequency submucosal tissue volume reduction is a safe and effective method of treating symptomatic obstructive tonsillar hypertrophy. It is well tolerated by the patient under local anesthesia in the physician's office and has minimal postprocedure pain and dysphagia, with rapid return to normal activity. The procedure reduces tonsil size and increases airway size, leading to a reduction in symptoms.
authors.affiliation: Somnus Medical Technologies, Inc, Sunnyvale, Calif, USA.
authors.forename: L M
authors.initials: LM
authors.lastname: Nelson
mesh_terms: D000328:Adult; D017115:Catheter Ablation; D002908:Chronic Disease; D006801:Humans; D006984:Hypertrophy; D008875:Middle Aged; D014066:Palatine Tonsil / Q000473:pathology* / Q000601:surgery; D010608:Pharyngeal Diseases / Q000601:surgery*; D011446:Prospective Studies